Results 81 to 90 of about 5,158 (116)

Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study. [PDF]

ESMO Real World Data Digit Oncol
Cazzaniga ME, Cogliati V, Rossi E, Paris I, Borella F, Moretti G, Garrone O, Pistelli M, Palumbo R, Ferro A, Vici P, De Giorgi U, Madaro S, Coltelli L, Giordano M, Gambaro AR, Nicoletti SVL, Zustovich F, Landucci E, Gamucci T, Pepe FF, Galimberti S, Capici S.   +22 more
europepmc   +1 more source

The landscape of clonal hematopoiesis of indeterminate potential in long-term breast cancer survivors. [PDF]

Breast
Gálvez-Carvajal L, Comino-Méndez I, López-López E, Ríos A, Zamorano E, Sequero S, González Á, Ruíz S, Ocaña MC, Garrido-Aranda A, Lavado-Valenzuela R, Rueda-Domínguez A, Pascual J, Alba E.   +13 more
europepmc   +1 more source

Correction: Rodríguez-Bautista et al. Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior. <i>Cancers</i> 2021, <i>13</i>, 6256. [PDF]

Cancers (Basel)
Rodríguez-Bautista R, Caro-Sánchez CH, Cabrera-Galeana P, Alanis-Funes GJ, Gutierrez-Millán E, Ávila-Ríos S, Matías-Florentino M, Reyes-Terán G, Díaz-Chávez J, Villarreal-Garza C, Hernández-Pedro NY, Ortega-Gómez A, Lara-Mejía L, Rangel-Escareño C, Arrieta O.   +14 more
europepmc   +1 more source

Presentacion

Arbor: Ciencia, Pensamiento y Cultura, 2015
Pilar Garrido, Dolores Isla
doaj  

[Treatment with dabrafenib and trametinib in an intrahepatic cholangiocarcinoma harboring a BRAF V600E mutation]. [PDF]

An Sist Sanit Navar
Gámiz Rejano A, Gago Sánchez AI, Rodríguez Alonso RM.   +2 more
europepmc   +1 more source

Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer. [PDF]

Breast
Gianni L, Delaloge S, Ciruelos E, Trédan O, Castañeda C, Abreu MH, Paris I, Colleoni M, Scandurra G, Kwiatkowski M, Antone N, Gregorc V, Tagliaferri P, Borštnar S, Blancas I, Raimondo M, Alfie M, Arce-Salinas C, Madeira PS, Lin YG, Ye C, Koli K, Mouta J, Martin M.   +23 more
europepmc   +1 more source

Adherence to Aromatase Inhibitor Therapy in Breast Cancer: Insights From a Multicenter Italian Study. [PDF]

Breast J
Fabbri MA, Fulvi A, Vergati M, D'Auria G, Vici P, Filomeno L, Arcuri T, Palazzo A, Nelli F, Fiore C, Portarena I, Falbo PT, Rossi R, Alesini D, Sini V, Pace R, Frittelli P, Corsi DC, Palombi L, Pisegna S, Botticelli A, Scagnoli S, Pistillucci G, Giordani E, La Cesa A.   +24 more
europepmc   +1 more source

Retraction Note: Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer. [PDF]

Br J Cancer
Rosa R, Damiano V, Nappi L, Formisano L, Massari F, Scarpa A, Martignoni G, Bianco R, Tortora G.   +8 more
europepmc   +1 more source

DPYD Genotyping of Patients with Fluoropyrimidine Treatment: Results of Protocol Implementation and Outcomes of Patients Carrying Unusual DPYD Variants. [PDF]

Genes (Basel)
Salgado Garrido J, Alonso Llorente A, Teijido Hermida O, Beloqui Lizaso JJ, Grández Ladrón de Guevara R, Velasco EM, Vera García R, Valiente Martín A.   +7 more
europepmc   +1 more source

[Fear of cancer recurrence and primary care utilization in women with breast cancer]. [PDF]

Aten Primaria
Garduño-Sánchez S, Iglesias-Melero C, Carrasco-Sánchez FJ, Gómez-Salgado J.   +3 more
europepmc   +1 more source